Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2008-12-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT00440154
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: placeboDrug: AVE1625
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 873
- Registration Number
- NCT00439634
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00437463
- Locations
- 🇭🇰
Sanofi-Aventis, Hong Kong, Hong Kong
Taxotere Prostate Cancer New Indication Registration Trial in China
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 228
- Registration Number
- NCT00436839
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT00436800
- Locations
- 🇭🇰
Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2010-11-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT00436293
- Locations
- 🇭🇰
Sanofi-Aventis, Hong Kong, Hong Kong
Amisulpride in Schizophrenic Acute Phase Patients
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT00436371
- Locations
- 🇭🇰
Sanofi-Aventis, Hong Kong, Hong Kong
Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.
- Conditions
- FeverPain
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT00434681
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 915
- Registration Number
- NCT00434096
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2009-04-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 810
- Registration Number
- NCT00432575
- Locations
- 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland